Treatment of Epstein-Barr Virus-associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: A case report and literature review

Hematology

Volumn 10, Issue 5, 2005, Pages 365-370

  Zhu, Kanger ^a   Chen, Jie ^a   Chen, Shengting ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

Epstein Barr virus; Lymphoproliferative disorder; Pure red cell aplasia; Rituximab; Stem cell transplant; Therapy

Indexed keywords

LATENT MEMBRANE PROTEIN 1; RITUXIMAB;

ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CASE REPORT; CERVICAL LYMPH NODE; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DRUG RESPONSE; EPSTEIN BARR VIRUS ASSOCIATED LYMPHOPROLIFERATIVE DISORDER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLAST; IMMUNOCYTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERSTITIAL PNEUMONIA; LYMPH NODE BIOPSY; LYMPHOPROLIFERATIVE DISEASE; MUCOSA INFLAMMATION; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PURE RED CELL ANEMIA; STEM CELL TRANSPLANTATION; UMBILICAL CORD BLOOD; VIRUS GENE;

ABO BLOOD-GROUP SYSTEM; ANTIBODIES, MONOCLONAL; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HISTOCOMPATIBILITY TESTING; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LYMPHOPROLIFERATIVE DISORDERS; RED-CELL APLASIA, PURE;

EID: 29144497402     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330410001714202     Document Type: Article

References (24)

1. Ohga S, Kanaya Y, Maki H, et al. Epstein-Barr virus-associated lymphoproliferative disease after a cord blood transplant for Diamond-Blakfan anemia. Bone Marrow Transplant 2000;25:209-212.
2. Loren AW, Porter DL, Stadtmauer EA, et al. Post-transplant lymphoproliferative disorder: A review. Bone Marrow Transplant 2003;31:145-155.
3. Abed N, Casper JT, Camitta BM, et al. Evaluation of histogenesis of B-lymphocytes in pediatric EBV-related posttransplant lymphoproliferative disorders. Bone Marrow Transplant 2004;33:321 -327.
4. Micallef IN, Chhanabhai M, Gascoyne RD, et al. Lymphoproliferative disorders following allogeneic bone marrow transplantation: The Vancouver experience. Bone Marrow Transplant 1998;22:981-987.
5. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 1999;94:2208-2216.
6. Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988;72:520-529.
7. Juvonen E, Aalto SM, Tarkkanen J, et al. High incidence of PTLD after non-T-cell-depleted allogeneic hematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant 2003;32:97-102.
8. Nasb RA, Dansey R, Storek J, et al. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune disease. Bio Blood Marrow Transplant 2003;9:583-591.
9. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993;328:593-602.
10. Barker JN, Martin PL, Coad JE, et al. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Bio Blood Marrow Transplant 2001;7:395-399.
11. Deeg HJ, Socie G. Malignancies after hematopoietic stem cell transplantation: Many questions, some answers. Blood 1998;91:1833-1844.
12. Hoshino Y, Kimura H, Kuzushima K, et al. Early intervention in post-transplant lymphoproliferative disorders based on Epstein-Barr viral load. Bone Marrow Transplant 2000; 26:199-201.
13. Gross TG, Steinbush M, DeFor T, et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: Risk factors, treatment and outcome. Bone Marrow Transplant 1999;23:251-258.
14. Benkerrou M, Jais JP, Leblond V, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome. Blood 1998;92:3137-3147.
15. Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (Rituximab) for therapy of Epstein-Barr virus lymphoma after hematopoietic stem cell transplantation. Blood 2000; 95:1502-1505.
16. Faye A, Quartier P, Reguerre Y, et al. Chimaeric anti-CD20 monoclonal antibody (Rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001;115:112-118.
17. Skoda-Smith S, Douglas PK, Mehta P, et al. Treatment of post-transplant lymphoproliferative disorder with induction chemotherapy, followed by haploidentical peripheral blood stem cell transplantation and Rituximab. Bone Marrow Transplant 2001;27:329-332.
18. Haddad E, Paczesny S, Leblond V, et al. Treatment of B- lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: A multicenter phase 1-2 clinical trial. Blood 2001;97:1590-1597.
19. Al-OKK H, Diaz B, Stives S, et al. Successful resolution of pure red cell aplasia (PRCA) following major ABO incompatible unrelated donor stem cell transplantation using Rituximab. Blood 2003;102, lb-Abstract 5478.
20. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusion of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-1191.
21. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997;276:1719-1724.
22. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-1555.
23. Lankester AC, van Tol MJ, Vossen JM, et al. Epstein-Barr virus (EBV)-DNA quantification in pediatric allogeneic stem cell recipients: Prediction of EBV-associated lymphoproliferative disease. Blood 2002;99:2630-2631.
24. van Esser JW, Niesters HG, Van Der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high risk patients after allogeneic stem cell transplantation. Blood 2002;99:4364-4369.